ATE516499T1 - Hilfsverfahren zur diagnose und therapie von krebs mit nucleolin - Google Patents

Hilfsverfahren zur diagnose und therapie von krebs mit nucleolin

Info

Publication number
ATE516499T1
ATE516499T1 AT06722440T AT06722440T ATE516499T1 AT E516499 T1 ATE516499 T1 AT E516499T1 AT 06722440 T AT06722440 T AT 06722440T AT 06722440 T AT06722440 T AT 06722440T AT E516499 T1 ATE516499 T1 AT E516499T1
Authority
AT
Austria
Prior art keywords
nucleolin
endostatin
kit
antibody
diagnosis
Prior art date
Application number
AT06722440T
Other languages
English (en)
Inventor
Yongzhang Luo
Hubing Shi
Zhuobing Zhang
Original Assignee
Univ Tsinghua
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tsinghua, Protgen Ltd filed Critical Univ Tsinghua
Application granted granted Critical
Publication of ATE516499T1 publication Critical patent/ATE516499T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
AT06722440T 2005-05-12 2006-05-11 Hilfsverfahren zur diagnose und therapie von krebs mit nucleolin ATE516499T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2005100117073A CN1862258B (zh) 2005-05-12 2005-05-12 核仁素辅助的癌症诊断与治疗方法
PCT/CN2006/000942 WO2006119706A1 (fr) 2005-05-12 2006-05-11 Procede auxiliaire de diagnostic et traitement du cancer a la nucleoline

Publications (1)

Publication Number Publication Date
ATE516499T1 true ATE516499T1 (de) 2011-07-15

Family

ID=37389730

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06722440T ATE516499T1 (de) 2005-05-12 2006-05-11 Hilfsverfahren zur diagnose und therapie von krebs mit nucleolin

Country Status (11)

Country Link
US (3) US20060258605A1 (de)
EP (2) EP2375251B1 (de)
JP (3) JP4742142B2 (de)
CN (2) CN102539734B (de)
AT (1) ATE516499T1 (de)
AU (2) AU2006246197B2 (de)
CA (1) CA2607832A1 (de)
DK (1) DK1912066T3 (de)
ES (2) ES2369383T3 (de)
HK (2) HK1114903A1 (de)
WO (1) WO2006119706A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
CN102539734B (zh) 2005-05-12 2016-02-03 清华大学 核仁素辅助的癌症诊断与治疗方法
WO2009088837A2 (en) * 2007-12-31 2009-07-16 The University Of Louisville Research Foundation, Inc. Methods and products to target, capture and characterize stem cells
CN108707584A (zh) * 2009-11-17 2018-10-26 Musc研究发展基金会 针对人核仁素的人单克隆抗体
WO2011123945A1 (en) * 2010-04-06 2011-10-13 The University Of British Columbia Compostions, methods and uses for treating respiratory syncytial virus infection
ES2880291T3 (es) 2011-06-02 2021-11-24 Univ Louisville Res Found Inc Nanopartículas conjugadas a un agente antinucleolina
US20130023479A1 (en) * 2011-07-22 2013-01-24 Protgen Ltd. Use of nucleolin as a biomarker for lymphangiogenesis in cancer prognosis and therapy
WO2016179394A1 (en) 2015-05-05 2016-11-10 Malik Mohammad Tariq Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
WO2017011411A1 (en) * 2015-07-10 2017-01-19 Ohio State Innovation Foundation Methods and compositions relating to anti-nucleolin recombinant immunoagents
CN106405084A (zh) * 2015-07-31 2017-02-15 复旦大学附属华山医院 核仁素在制备肠癌诊断试剂和治疗药物中的应用
CN106405096A (zh) * 2015-07-31 2017-02-15 复旦大学附属华山医院 核仁素在制备胃癌诊断试剂和治疗药物中的应用
WO2017181049A1 (en) * 2016-04-15 2017-10-19 Charlestonpharma, Llc Anti-nucleolin agents
CN116754768B (zh) * 2023-05-30 2024-03-29 中山大学附属第五医院 Ddx24在维持内皮细胞的核仁稳态中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981785A (en) 1988-06-06 1991-01-01 Ventrex Laboratories, Inc. Apparatus and method for performing immunoassays
US5376313A (en) 1992-03-27 1994-12-27 Abbott Laboratories Injection molding a plastic assay cuvette having low birefringence
US5639606A (en) 1993-04-06 1997-06-17 The University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5876978A (en) 1993-04-06 1999-03-02 Medical College Of Ohio Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5643765A (en) 1993-04-06 1997-07-01 University Of Rochester Method for quantitative measurement of gene expression using multiplex competitive reverse transcriptase-polymerase chain reaction
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
JP2000502450A (ja) 1995-12-22 2000-02-29 アボツト・ラボラトリーズ 蛍光偏光免疫アッセイによる診断法
US5885529A (en) 1996-06-28 1999-03-23 Dpc Cirrus, Inc. Automated immunoassay analyzer
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
CN1266064A (zh) * 1999-03-03 2000-09-13 华西医科大学 血管生成抑制因子—内皮抑素及其制备方法
JP2003180368A (ja) * 2001-12-19 2003-07-02 Pharma Design Inc 癌患者に対する放射線治療の有効性の予測方法
US7544767B2 (en) * 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
WO2003087124A2 (en) * 2002-04-05 2003-10-23 The Burnham Institute Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
GB0209893D0 (en) * 2002-04-30 2002-06-05 Molmed Spa Conjugate
US7470667B2 (en) * 2002-12-05 2008-12-30 Medgenn (Hong Kong) Ltd Methods of treating cancer using a modified endostatin protein
US7078485B2 (en) 2002-12-05 2006-07-18 Yantai Medgenn Ltd. N-terminal modified recombinant human endostatin and its production
EP2233926A3 (de) * 2003-04-01 2011-01-12 The Johns Hopkins University Endothelzellen-Expressionsmuster in der Brust
WO2004104227A1 (en) * 2003-05-20 2004-12-02 Pfizer Products Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
CN102539734B (zh) 2005-05-12 2016-02-03 清华大学 核仁素辅助的癌症诊断与治疗方法

Also Published As

Publication number Publication date
JP2008541066A (ja) 2008-11-20
AU2010241351B2 (en) 2013-04-04
CA2607832A1 (en) 2006-11-16
CN102539734A (zh) 2012-07-04
JP4742142B2 (ja) 2011-08-10
HK1114903A1 (en) 2008-11-14
CN1862258B (zh) 2012-05-30
JP5502652B2 (ja) 2014-05-28
EP1912066A4 (de) 2008-10-15
EP1912066A1 (de) 2008-04-16
US20060258605A1 (en) 2006-11-16
EP2375251A1 (de) 2011-10-12
US11434288B2 (en) 2022-09-06
EP2375251B1 (de) 2015-04-08
EP1912066B1 (de) 2011-07-13
DK1912066T3 (da) 2011-10-24
AU2006246197A1 (en) 2006-11-16
JP5758962B2 (ja) 2015-08-05
US20230174644A1 (en) 2023-06-08
ES2369383T3 (es) 2011-11-30
ES2538344T3 (es) 2015-06-19
HK1162667A1 (en) 2012-09-21
JP2011013225A (ja) 2011-01-20
JP2014032203A (ja) 2014-02-20
AU2010241351A1 (en) 2010-12-02
CN102539734B (zh) 2016-02-03
US20090191224A1 (en) 2009-07-30
AU2006246197B2 (en) 2010-08-19
WO2006119706A1 (fr) 2006-11-16
CN1862258A (zh) 2006-11-15

Similar Documents

Publication Publication Date Title
ATE516499T1 (de) Hilfsverfahren zur diagnose und therapie von krebs mit nucleolin
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
ATE450547T1 (de) Eml4-alk-fusionsgen
EP3070097A3 (de) Citrullinierte peptide zur diagnose und prognose von rheumatoider arthritis
WO2004037999A3 (en) A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same
JP2008249727A5 (de)
WO2005001092A3 (en) Compositions and methods for diagnosing and treating cancers
EP2009115A3 (de) Verfahren und Nukleinsäuren für Analysen von Zellwucher-Störungen
WO2010023327A4 (en) Method for obtaining oligonucleotide aptamers and uses thereof
TW200626900A (en) Wnt proteins and detection and treatment of cancer
WO2006036173A3 (en) Frizzled proteins and detection and treatment of cancer
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2006034328A3 (en) Wnt proteins and detection and treatment of cancer
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
ATE514090T1 (de) Verwendung des proteins satb2 als marker zur unterscheidung kolorektaler karzinome von anderen krebserkrankungen
WO2002022879A3 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2009019367A3 (fr) Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal
MX2007008984A (es) Marcadores de cancer y metodos de deteccion.
WO2002031209A3 (en) Genes related to development of refractory prostate cancer
Li et al. DNA-silver nanoclusters/polypyrrole nanoparticles: a label-free and enzyme-free platform for multiplexed transcription factors detection
WO2007112054A3 (en) Facilitation of translocation of molecules through the gastrointestinal tract
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
HK1126278A1 (en) Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha pdgfr(nsclc)
WO2004066933A3 (en) Compositions and methods for treating cancer using igsf9 and liv-1

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1912066

Country of ref document: EP